Athira pharma presents study overview and baseline data from act-ad phase 2 trial of fosgonimeton in mild-to-moderate alzheimer's disease at the 2022 ad/pd™ congress

Bothell, wash., march 20, 2022 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that study overview and baseline data from act-ad, a fully enrolled phase 2 clinical trial of athira's lead development candidate, fosgonimeton (ath-1017) in study participants with mild-to-moderate alzheimer's disease (ad), were presented in an oral presentation at the international conference on alzheimer's and parkinson's disease and related neurological diseases (ad/pd™ 2022) taking place in barcelona, spain, and virtually from march 15-20, 2022.
ATHA Ratings Summary
ATHA Quant Ranking